Aimmune Therapeutics (AIMT) PT Lowered to $52 at RBC Capital
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 18 | New: 28
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $52.00 (from $54.00) while maintaining a Outperform rating.
You May Also Be Interested In
- JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral
- VersaBank (VBNK) PT Lowered to $20 at Raymond James
- CLSA Upgrades Taiyo Yuden Co Ltd (6976:JP) (TYOYY) to High-Conviction Outperform (1)
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
